MDACC Study No:2011-0073 ( NCT No: NCT01409174)
Title:IPI-Biochemotherapy for Chemonaive Patients with Metastatic Melanoma
Principal Investigator:Rodabe N. Amaria
Treatment Agent:Cisplatin; Interferon alfa 2b; Interleukine 2; Ipilimumab; Temozolomide
Study Status:Closed
Study Description:The goal of the Phase I part of this clinical research study is to find the
highest tolerable dose of the drug Yervoy (ipilimumab) that can be given with
the drugs Temodar (temozolomide), Intron-A (interferon alfa-2b), Proleukin
(aldesleukin, IL-2), and Platinol (cisplatin) to patients with metastatic
melanoma. The safety of this combination will also be studied in Phase I. The
goal of Phase II is to learn if this combination can help to control metastatic

Ipilimumab, interferon alfa-2b, and aldesleukin are designed to block the
activity of cells that decrease the immune system's ability to fight cancer.

Temozolomide is designed to stop cancer cells from making new DNA (the genetic
material of cells). This may stop the cancer cells from dividing into new

Cisplatin is designed to poison the cancer cells, which may cause them to die.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I/Phase II
Treatment Agents:Cisplatin
Interferon alfa 2b
Interleukine 2
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Rodabe N. Amaria
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults